Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › TG103

TG103

GLP-1 · s.c. · CSPC

Data cut 12 November 2026 · page built 16 November 2026 · 2 trial arms · 2 trials with results · 3 registered trials · see on the pipeline board

Summary

Also known as
CSPC
Mechanism
GLP-1
Route
s.c.
Company
CSPC
Highest development stage
filed
Status (as of data cut)
Efmedaglutide alfa. Phase 3 T2D non-inferior to dulaglutide; obesity NDA accepted in China (Oct 2025) verify
Next milestone
China approval

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingObesity NDA accepted in China (Oct 2025); phase 3 numbers not publishedCSPC announcement (Oct 2025)
T2D3 positive phase 3Phase 3 non-inferiority versus dulaglutide metTG103 vs dulaglutide (EASD 2026)
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
Phase III TG103 + metformin vs dulaglutide (EASD 2026)15 mg QW vs dulaglutide 1.5 mg QW (active comparator): HbA1c -1.25t2d china52211——−1.3——————press release
TG103 phase 3 vs dulaglutide (T2D)TG103 15 mg vs dulaglutide: HbA1c −1.38 %t2d china28———−1.4——————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (1)
  • 15 mg QW · hba1c · HKEX filing
    Injection 15 mg group was higher than that in the dulaglutide 1.5 mg group (1.31% vs 1.25%),

Registered trials (3)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT06235086
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
T2DPhase 3completed2024-04 → 2026-02632Completed; results not in the atlas yetNCT06235086
NCT06258148
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
T2DPhase 3completed2024-04 → 2026-01465Completed; results not in the atlas yetNCT06258148
NCT05997576
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
ObesityPhase 3completed2023-11 → 2025-02675Completed; results not in the atlas yetNCT05997576

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TG103. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/tg103/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.